Instil Bio resumes Phase 1 trial of ITIL-306; initial data expected in 2023

Instil Bio, Inc.

Phase 1 trial of ITIL-306 (CoStAR-TIL) for NSCLC, ovarian, and renal cancer re-opened after voluntary pause.
Initial safety, translational, and efficacy data from dose escalation cohorts expected in 2023.
Resumption follows implementation of additional quality safeguards in manufacturing process.
Company expects cash runway into 2025, excluding potential monetization of Tarzana manufacturing site.
Recent reprioritization of clinical programs and corporate restructuring completed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.